Growing evidence has revealed the crucial role of CXCL8-CXCR1/2 axis in the TME and prognostic significance of the CXCL8 serum level in human cancer, following immune checkpoint blockade therapy (58, 238–240). This evidence concerns the gene CXCR1 and cancer.